3 Key Takeaways
Plain English Summary- 01Core Finding
To address this gap, we conducted a pharmacogenomic genome-wide association study (GWAS) in a randomized comparative effectiveness trial to identify genetic predictors of glycemic response to insulin glargine, glimepiride, liraglutide, and sitagliptin when added to metformin.
- 02Study Evidence
Tested in a genetic / mendelian study + randomized controlled trial at the randomized clinical trial stage.
- 03Practical Meaning
Genetic / Mendelian randomization findings highlight causal biological risk, but ancestry coverage and pleiotropy can limit generalizability.
What This Means for You
Genetic variation influences glycemic response to glucose-lowering medications, with SLC2A2 emerging as a genetic factor that modulates sulfonylurea response. These findings warrant further study to evaluate whether low-response allele carriers would benefit from alternative glucose-lowering therapies to advance precision diabetes care.
The Discovery
Optimizing second-line therapy for type 2 diabetes remains challenging because of interindividual variability in response. Current treatment selection does not consider personal genetic profiles. To address this gap, we conducted a pharmacogenomic genome-wide association study (GWAS) in a randomized comparative effectiveness trial to identify genetic predictors of glycemic response to insulin glargine, glimepiride, liraglutide, and sitagliptin when added to metformin. In the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study (GRADE), we performed a GWAS for the time to reach primary (glycated hemoglobin [HbA1c] ≥a clinically meaningful level) and secondary (HbA1c >7.5%) metabolic failure. We conducted replication in independent cohorts, performed fine mapping of the top variants near SLC2A2, evaluated them for physiologic impact using oral glucose tolerance testing (OGTT) and response to acute glipizide challenge, and characterized glycemic response to glimepiride in an slc2a2-mutated zebrafish model. rs2129019 in SLC2A2 encoding GLUT2 was enriched in African/African American participants and conferred a a clinically meaningful level increased risk of metabolic failure per A allele on glimepiride (P = 1.55 × 10-8). Carriers had impaired β-cell function, evidenced by a lower C-peptide index during OGTT, and diminished glucose-lowering response to acute sulfonylurea challenge. Genetic manipulation in zebrafish confirmed that slc2a2 disruption attenuated the glucose-lowering effect of glimepiride.
How It Works, Simply
This endocrinology research focuses on insulin · Genetics. Researchers evaluated it using a genetic / Mendelian study + Randomized controlled trial at the randomized clinical trial stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
To address this gap, we conducted a pharmacogenomic genome-wide association study (GWAS) in a randomized comparative effectiveness trial to identify genetic predictors of glycemic response to insulin glargine, glimepiride, liraglutide, and sitagliptin when added to metformin.
- 02Study Evidence
Tested in a genetic / mendelian study + randomized controlled trial at the randomized clinical trial stage.
- 03Practical Meaning
Genetic / Mendelian randomization findings highlight causal biological risk, but ancestry coverage and pleiotropy can limit generalizability.
Key Numbers
Biological Mechanism & Study Design
Study Design & Cohort
Genetic / Mendelian study + Randomized controlled trial
Genetic / Mendelian study + Randomized controlled trial · Randomized Clinical Trial
Biological Pathway & Modality
Insulin · Genetics
Intervention: Common Genetic Variants Near SLC2A2 and Glycemic Response to Glimepiride in the
Experimental Findings & Endpoints
Optimizing second-line therapy for type 2 diabetes remains challenging because of interindividual variability in response.
Current treatment selection does not consider personal genetic profiles. To address this gap, we conducted a pharmacogenomic genome-wide association study (GWAS) in a randomized comparative effectiveness trial to identify genetic predictors of glycemic response to insulin glargine, glimepiride, liraglutide, and sitagliptin when added to metformin.
In the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study (GRADE), we performed a GWAS for the time to reach primary (glycated hemoglobin [HbA1c] ≥a clinically meaningful level) and secondary (HbA1c >7.5%) metabolic failure. We conducted replication in independent cohorts, performed fine mapping of the top variants near SLC2A2, evaluated them for physiologic impact using oral glucose tolerance testing (OGTT) and response to acute glipizide challenge, and characterized glycemic response to glimepiride in an slc2a2-mutated zebrafish model. rs2129019 in SLC2A2 encoding GLUT2 was enriched in African/African American participants and conferred a a clinically meaningful level increased risk of metabolic failure per A allele on glimepiride (P = 1.55 × 10-8).
Carriers had impaired β-cell function, evidenced by a lower C-peptide index during OGTT, and diminished glucose-lowering response to acute sulfonylurea challenge. Genetic manipulation in zebrafish confirmed that slc2a2 disruption attenuated the glucose-lowering effect of glimepiride.
Clinical Translation & Practice Context
Genetic variation influences glycemic response to glucose-lowering medications, with SLC2A2 emerging as a genetic factor that modulates sulfonylurea response.
These findings warrant further study to evaluate whether low-response allele carriers would benefit from alternative glucose-lowering therapies to advance precision diabetes care.
The Bottom Line · Clinical Pearl
“Genetic variation influences glycemic response to glucose-lowering medications, with SLC2A2 emerging as a genetic factor that modulates sulfonylurea response.”
Published in Diabetes Care · Current Stage: Randomized Clinical Trial